Molecular pathways and crosstalk characterizing the cardiorenal syndrome

OMICS A Journal of Integrative Biology

Volumn 16, Issue 3, 2012, Pages 105-112

  Mühlberger, Irmgard ^a   Mönks, Konrad ^a   Fechete, Raul ^a   Mayer, Gert ^b   Oberbauer, Rainer ^c,d   Mayer, Bernd ^a,e   Perco, Paul ^a,d  

^a Emergentec Biodevelopment GmbH   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADIPOCYTOKINE RECEPTOR; ALBUMIN; APOLIPOPROTEIN A1; ARACHIDONIC ACID; CHEMOKINE RECEPTOR; CYTOKINE; GLUTATHIONE; GLYCOSAMINOGLYCAN; HISTIDINE; ISOLEUCINE; LEUCINE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PURINE; TERPENOID; THIOCTIC ACID; TYROSINE; VALINE; VASOPRESSIN;

ARACHIDONIC ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD CLOTTING; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CYTOKINE PRODUCTION; DIABETIC NEUROPATHY; DISEASE COURSE; DISORDERS OF CARBOXYLIC ACID METABOLISM; DYSLIPIDEMIA; FOCAL ADHESION; GENETIC ANALYSIS; GLUTATHIONE METABOLISM; GLYCOSAMINOGLYCAN METABOLISM; HEART CONTRACTION; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; MISMATCH REPAIR; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PURINE METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH ACID; STOMACH ACID SECRETION; TRANSCRIPTOMICS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UBIQUITINATION; VASOPRESSIN RELEASE; WATER ABSORPTION;

EID: 84859801582     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2011.0121     Document Type: Article

References (43)

1. Anavekar, N.S., McMurray, J.J.V., Velazquez, E.J., Solomon, S.D., Kober, L., Rouleau, J.-L., et al.. (2004). Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351, 1285-1295 (Pubitemid 39258422)
2. Andrikoula, M., and McDowell, I.F.W. (2008). The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 10, 271-278 (Pubitemid 351386024)
3. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., et al.. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29 (Pubitemid 30257031)
4. Attman, P.O., Knight-Gibson, C., Tavella, M., Samuelsson, O., and Alaupovic, P. (1998). The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13, 2833-2841 (Pubitemid 28479531)
5. Berl, T., and Henrich, W. (2006). Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 1, 8-18
6. Bongartz, L.G., Cramer, M.J., Doevendans, P.A., Joles, J.A., and Braam, B. (2005). The severe cardiorenal syndrome: "Guyton revisited." Eur Heart J 26, 11-17 (Pubitemid 40221118)
7. Border, W.A., Yamamoto, T., and Noble, N.A. (1996). Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev 12, 309-339 (Pubitemid 27062225)
8. Dahl, C.P., Gullestad, L., Fevang, B., Holm, A.M., Landrø, L., Vinge, L.E., et al.. (2008). Increased expression of LIGHT/ TNFSF14 and its receptors in experimental and clinical heart failure. Eur J Heart Failure 10, 352-359
9. Fassot, C., Briet, M., Rostagno, P., Barbry, P., Perret, C., Laude, D., et al.. (2008). Accelerated arterial stiffening and gene expression profile of the aorta in patients with coronary artery disease. J Hypertens 26, 747-757 (Pubitemid 351354923)
10. Fechete, R., Heinzel, A., Perco, P., Mönks, K., Söllner, J., Stelzer, G., et al.. (2011). Mapping of molecular pathways, biomarkers and drug targets for diabeticnephropathy. Proteomics Clin Appl 5, 354-366
11. Gilbert, R.E., and Cooper, M.E. (1999). The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56, 1627-1637 (Pubitemid 29518163)
12. Judson, W.E., and Helmer, O.M. (1971). Relationship of cardiorenal function to renin-aldosterone system in patients with valvular heart disease. Circulation 44, 245-253
13. Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27-30 (Pubitemid 30047706)
14. Kannel, W.B. (2005). Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40, 1215-1220 (Pubitemid 43117845)
15. Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I., Bridge, A., Derow, C., et al.. (2007). IntAct-open source resource for molecular interaction data. Nucleic Acids Res 35, D561-D565 (Pubitemid 46056270)
16. Kim, K.J., Yang, W.S., Kim, S.B., Lee, S.K., and Park, J.S. (1997). Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Peritoneal Dial Int 17, 157-161 (Pubitemid 27474772)
17. Kirmizis, D., Tsiandoulas, A., Pangalou, M., Koutoupa, E., Rozi, P., Protopappa, M., et al.. (2006). Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monitor 12, CR55-CR62 (Pubitemid 43200944)
18. Koniari, K., Nikolaou, M., Paraskevaidis, I., and Parissis, J. (2010). Therapeutic options for the management of the cardiorenal syndrome. Int J Nephrol 2011, 194910
19. Kurata, A., Nishizawa, H., Kihara, S., Maeda, N., Sonoda, M., Okada, T., et al.. (2006). Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70, 1717-1724 (Pubitemid 44684802)
20. Lee, C.R., Watkins, M.L., Patterson, J.H., Gattis, W., O'Connor, C.M., Gheorghiade, M., et al.. (2003). Vasopressin: a new target for the treatment of heart failure. Am Heart J 146, 9-18 (Pubitemid 36851295)
21. Letavernier, E., Perez, J., Joye, E., Bellocq, A., Fouqueray, B., Haymann, J.-P., et al.. (2005). Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16, 2395-2402 (Pubitemid 41725057)
22. Lindner, A., Charra, B., Sherrard, D.J., and Scribner, B.H. (1974). Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290, 697-701
23. Lynch, A.I., Boerwinkle, E., Davis, B.R., Ford, C.E., Eckfeldt, J.H., Leiendecker-Foster, C., et al.. (2009). Antihypertensive pharmacogenetic effect of fibrinogen-beta variant - 455G >A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics 19, 415-421
24. McCullough, P.A., and Verrill, T.A. (2010). Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 122, 25-34
25. Mitchell, D.A., Taylor, P.R., Cook, H.T., Moss, J., Bygrave, A.E., Walport, M.J., et al.. (1999). Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol 162, 5676-5679 (Pubitemid 29314916)
26. Morange, P.E., Bickel, C., Nicaud, V., Schnabel, R., Rupprecht, H.J., Peetz, D., et al.. (2006). Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 26, 2793-2799
27. Mühlberger, I., Moenks, K., Bernthaler, A., Jandrasits, C., Mayer, B., Mayer, G., et al.. (2010). Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. Int J Nephrol 2011, 809378
28. Nath, K.A. (1998). The tubulointerstitium in progressive renal disease. Kidney Int 54, 992-994 (Pubitemid 28397421)
29. Perco, P., Mühlberger, I., Mayer, G., Oberbauer, R., Lukas, A., and Mayer, B. (2010). Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis 31, 1780-1789
30. Ronco, C., Haapio, M., House, A.A., Anavekar, N., and Bellomo, R. (2008). Cardiorenal syndrome. J Am College Cardiol 52, 1527-1539
31. Ronco, C., McCullough, P.A., Anker, S.D., Anand, I., Aspromonte, N., Bagshaw, S.M., et al.. (2010). Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 165, 54-67
32. Rostand, S.G., Kirk, K.A., and Rutsky, E.A. (1986). The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management. Contrib Nephrol 52, 34-41
33. Ryan, K.E., McCance, D.R., Powell, L., McMahon, R., and Trimble, E.R. (2007). Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194, e123-e130 (Pubitemid 47513101)
34. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., et al.. (2003). Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42, 1050-1065 (Pubitemid 37413751)
35. Schiffrin, E.L. (2005). More evidence of cardiorenal protective effects of peroxisome proliferator-activated receptor activation. Hypertension 46, 267-268 (Pubitemid 41099154)
36. Schiffrin, E.L., Lipman, M.L., and Mann, J.F.E. (2007). Chronic kidney disease: effects on the cardiovascular system. Circulation 116, 85-97 (Pubitemid 47016250)
37. Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., et al.. (2006). Modular activation of nuclear factor- kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55, 2993-3003 (Pubitemid 44923635)
38. Silverstein, D.M. (2009). Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24, 1445-1452
39. Sjøland, J.A., Sidelmann, J.J.,Brabrand,M.,Pedersen, R.S.,Pedersen, J.H., Esbensen, K., et al.. (2007). Fibrin clot structure in patients with end-stage renal disease. Thromb Haemostasis 98, 339-345 (Pubitemid 47250237)
40. Toyoda, T., Kamei, Y., Kato, H., Sugita, S., Takeya, M., Suganami, T., et al.. (2008). Effect of peroxisome proliferatoractivated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity 16, 1199-1207 (Pubitemid 351771340)
41. Volger, O.L., Fledderus, J.O., Kisters, N., Fontijn, R.D., Moerland, P.D., Kuiper, J., et al.. (2007). Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol 171, 326-337 (Pubitemid 47339249)
42. Werner, C., Kamani, C.H., Gensch, C., Bohm, M. and Laufs, U. (2007). The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56, 2609-2615 (Pubitemid 47523269)
43. Williams, J.M., Zhao, X., Wang, M.H., Imig, J.D. and Pollock, D.M. (2005). Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 46, 366-371 (Pubitemid 41099171)